当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.

Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.

Abstract：

:We investigated the prognostic relevance of IKZF1 deletions in 118 adult Ph-positive ALL patients who had minimal residual disease (MRD) data under a uniform treatment of allo-SCT following first-line imatinib-based chemotherapy. IKZF1 deletions were identified in 93 patients (78.8%). IKZF1-deleted patients had a lower proportion of early-stable molecular responders compared with wild-type patients (28.0 vs 56.0%, P=0.028). After a median follow-up of 72 months, IKZF1-deleted patients had a trend for higher cumulative incidence of relapse (CIR) (38.0 vs 13.3%, P=0.052), particularly in a subgroup of early-stable molecular responders (n=40; 21.4 vs 0%, P=0.088), but comparable disease-free survival to wild-type patients. Patients with biallelic-null deletions showed higher CIR (74.6 vs 13.3%, P=0.003) and lower disease-free survival (20.0 vs 67.5%, P=0.022) than wild-type patients. In multivariate analysis, MRD kinetics were closely related to outcomes, while neither IKZF1 deletions nor their functional subtypes retained an independent statistical power. Within the limitation of sample size, however, considering both the negative impact of IKZF1 deletions on MRD kinetics and a trend for relationship between IKZF1 deletions and relapse in early-stable molecular responders, IKZF1 deletions may have a potentially additive effect on unfavorable prognosis in a specific MRD-based subgroup of adult Ph-positive ALL transplants.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Kim M,Park J,Kim DW,Kim YJ,Jeon YW,Yoon JH,Shin SH,Yahng SA,Lee SE,Cho BS,Eom KS,Kim HJ,Min CK,Cho SG,Kim Y,Lee JW,Han K,Min WS,Lee S

doi

10.1038/bmt.2014.281

subject

Has Abstract

pub_date

2015-03-01 00:00:00

pages

354-62

issue

3

eissn

0268-3369

issn

1476-5365

pii

bmt2014281

journal_volume

50

pub_type

杂志文章

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts.

    abstract：:Haploidentical hematopoietic stem cell transplantation using T-cell-depleted grafts is a valid option for pediatric patients with hematological malignancies in need of an allogeneic transplantation and lacking an HLA-identical donor. Seventy-five transplantations were performed in 70 patients. Thirty-eight patients ha...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2016.101

    authors： Diaz MA,Pérez-Martínez A,Herrero B,Deltoro N,Martinez I,Ramirez M,Abad L,Sevilla J,Merino E,Ruiz J,Vicario JL,Gonzalez-Vicent M

    更新日期：2016-09-01 00:00:00

  • No effect of nadroparin prophylaxis in the prevention of central venous catheter (CVC)-associated thrombosis in bone marrow transplant recipients.

    abstract：:Complications of CVCs in 382 consecutive patients receiving a stem cell transplantation (SCT) were analysed. Early complications were pneumothorax (3.6%), haematothorax (0.5%), dislocation (3%) and dysfunction (3.6%). Eighty-seven-associated infections (22%) were observed, leading to removal of the CVC in 26 patients....

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702675

    authors： Lagro SW,Verdonck LF,Borel Rinkes IH,Dekker AW

    更新日期：2000-11-01 00:00:00

  • Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.

    abstract：:Driven by access to better drugs, on average, newly diagnosed multiple myeloma patients have over 10 years overall survival. Using modern combination therapies-with or without the addition of high-dose melphalan and autologous stem cell transplantation-up to 80% of patients reach a complete response. As a logical and ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,meta分析

    doi：10.1038/bmt.2016.222

    authors： Landgren O,Devlin S,Boulad M,Mailankody S

    更新日期：2016-12-01 00:00:00

  • Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease.

    abstract：:We report a patient with pre-existing end-stage renal disease (ESRD) who underwent successful matched related donor allogeneic bone marrow transplantation for AML in second complete remission (CR2) using conditioning with high-dose cyclophosphamide (CY, 60 mg/kg/day x 2) and TBI (165 cGy twice daily x 4 days). The tim...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701646

    authors： Perry JJ,Fleming RA,Rocco MV,Petros WP,Bleyer AJ,Radford JE Jr,Powell BL,Hurd DD

    更新日期：1999-04-01 00:00:00

  • Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study.

    abstract：:We conducted a single-arm prospective study in 50 patients who received the combination of an haploidentical stem cell graft and an unrelated umbilical cord blood unit for the treatment of hematological malignancies. The median time for neutrophil engraftment was 13 days (11-20 days), and for platelets was 15 days (11...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2013.154

    authors： Chen J,Wang RX,Chen F,Sun AN,Qiu HY,Jin ZM,Tang XW,Han Y,Fu ZZ,He GS,Miao M,Ma X,Wu DP

    更新日期：2014-02-01 00:00:00

  • Elevated soluble human leukocyte antigen G levels in patients after allogeneic stem cell transplantation are associated with less severe acute and chronic graft-versus-host disease.

    abstract：:HLA-G is a non-classical class I molecule which induces tolerance in allogeneic situations by inhibition of cytotoxic NK and CD8 + T cells and by induction of regulatory T cells. Concordantly, in solid organ transplantation HLA-G is associated with a lower risk for acute and chronic rejection, whereas its role in allo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-018-0145-1

    authors： Kordelas L,da Silva Nardi F,Wagner B,Ditschkowski M,Liebregts T,Lindemann M,Heinemann FM,Horn PA,Beelen DW,Rebmann V

    更新日期：2018-09-01 00:00:00

  • Transplantation of unrelated donor umbilical cord blood utilizing double-unit grafts for five teenagers with transfusion-dependent thalassemia.

    abstract：:To augment graft cell dose, we evaluated the safety of the combined transplantation of two partially HLA-matched umbilical cord blood (UCB) units. Five patients with transfusion-dependent thalassemia, median age 11.1 years (range 10-13.1), received 2 UCB units after myeloablative conditioning. Cord blood units were a ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1705737

    authors： Jaing TH,Yang CP,Hung IJ,Chen SH,Sun CF,Chow R

    更新日期：2007-08-01 00:00:00

  • Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection.

    abstract：:In allo-stem cell transplantation (SCT), it is unclear whether donor-specific anti-HLA Abs (DSAs) can actually mediate graft rejection or if they are simply surrogate markers for the cellular immunity that causes graft rejection. Here, we first analyzed a case of cord blood allograft rejection in which DSA and cytotox...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2015.119

    authors： Hanajiri R,Murata M,Sugimoto K,Murase M,Sakemura R,Goto T,Watanabe K,Imahashi N,Terakura S,Ohashi H,Akatsuka Y,Kurahashi S,Miyamura K,Kiyoi H,Nishida T,Naoe T

    更新日期：2015-09-01 00:00:00

  • Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation.

    abstract：:The current study evaluates the role of quantitative measurement of peripheral lymphocyte subsets, especially CD4+ helper T-cell recovery, in predicting transplant outcomes including overall survival (OS) and non-relapse mortality (NRM) after allogeneic stem cell transplantation. A total of 69 allogeneic recipients we...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705381

    authors： Kim DH,Sohn SK,Won DI,Lee NY,Suh JS,Lee KB

    更新日期：2006-06-01 00:00:00

  • Role of marrow microenvironment in engraftment and maintenance of allogeneic hematopoietic stem cells.

    abstract：:Following allogeneic marrow transplantation a competent marrow microenvironment consists of a complex mixture of both donor and host derived cells. Clearly some forms of genetic disparity between donor and host can compromise appropriate interactions and function of these cells. The competency of the microenvironment ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Torok-Storb B,Holmberg L

    更新日期：1994-01-01 00:00:00

  • Hexaminolevulinate-mediated photodynamic purging of marrow grafts with murine breast carcinoma.

    abstract：:Photodynamic therapy (PDT) with porphyrin precursors is an established therapy for certain tumors. This study aimed to explore the use of hexaminolevulinate (HAL), a porphyrin precursor, for photodynamic purging of BM grafts contaminated with cells of the 4T1 breast carcinoma cell line. The optimal PDT dose was not ef...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2010.277

    authors： Čunderlíková B,Vasovič V,Sieber F,Furre T,Borgen E,Nesland JM,Peng Q

    更新日期：2011-08-01 00:00:00

  • Horse antilymphocytic globulin in hepatitis B exacerbation after bone marrow transplantation adoptive immunity transfer.

    abstract：:We describe the case of a HBsAg+, HBeAg+ carrier, treated with lamivudine, who experienced exacerbation of hepatitis after BMT from an anti-HBs+, anti-HBc+, anti-HBe+ donor. The serological profile of the donor and the timing of exacerbation suggested that the adoptive immunity transfer played a major pathogenetic rol...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704471

    authors： Favre C,Menconi MC,Nardi M,Casazza G,Oliveri F,Macchia P,Bonino F,Brunetto MR

    更新日期：2004-05-01 00:00:00

  • Relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings.

    abstract：:Data on 477 patients with hematologic malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings were analyzed for correlation between donor-recipient ABO blood group incompatibility and the development of elevated bilirubin levels (over 17 mmol/l) after transplantation. The median bili...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Mehta J,Powles R,Horton C,Milan S,Singhal S,Treleaven J

    更新日期：1995-06-01 00:00:00

  • Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis.

    abstract：:There have been encouraging reports of the use of recombinant tissue plasminogen activator (tPA) in established veno-occlusive disease (VOD). Haemodialysis has been considered a contraindication to this therapy in view of the potential haemostatic complications. We report a case of a woman who developed moderately sev...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Simpson DR,Browett PJ,Doak PB,Palmer SJ

    更新日期：1994-10-01 00:00:00

  • Clinically applicable bulk isolation of blood CD34+ cells for autografting in children.

    abstract：:CD34+ cells were purified in bulk from apheresis-collected cells of children with cancer using monoclonal antibody (MoAb) and magnetic beads (Baxter ISOLEX system). To improve the purity of the final product for possibly better tumor cell purging and to make the manufacturer's original procedure more cost-effective, w...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1701479

    authors： Kawano Y,Takaue Y,Law P,Watanabe T,Abe T,Okamoto Y,Makimoto A,Sato J,Nakagawa R,Kajiume T,Hirao A,Watanabe A,Kuroda Y

    更新日期：1998-11-01 00:00:00

  • Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens.

    abstract：:We retrospectively reviewed the pulmonary toxicity of six high dose chemotherapy protocols using four chemotherapy regimens in the treatment of solid tumors. All protocols used either high dose cyclophosphamide or ifosfamide in combination with one to three additional chemotherapeutic agents. In each protocol autologo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Seiden MV,Elias A,Ayash L,Hunt M,Eder JP,Schnipper LE,Frei E 3rd,Antman KH

    更新日期：1992-07-01 00:00:00

  • Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study.

    abstract：:Acute graft-versus-host disease (aGVHD) is a frequent and major complication after allogeneic stem cell transplantation. For many years psoralen and ultraviolet (UV)-A light have been used in the treatment of chronic cutaneous graft-versus-host disease, but few patients have received PUVA therapy for aGVHD. We assesse...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701537

    authors： Wiesmann A,Weller A,Lischka G,Klingebiel T,Kanz L,Einsele H

    更新日期：1999-01-01 00:00:00

  • Administration of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukemia: a note of caution.

    abstract：:A series of 22 consecutive pediatric patients undergoing ABMT for treatment of primary AML was reviewed in an efficacy analysis of recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF). Treatment with at least two cycles of chemotherapy and a standard conditioning regimen of busulfan and cycloph...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Calderwood S,Doyle JJ,Hitzler JK,Saunders EF,Freedman MH

    更新日期：1996-07-01 00:00:00

  • A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation.

    abstract：:We initiated a randomized study of amifostine (the organic thiophosphate formerly known as WR-2721) given to patients during myeloablative conditioning therapy for allogeneic bone marrow transplantation. Amifostine was given at a dose of 1000 mg/day of conditioning and was well tolerated if attention was given to seru...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1704521

    authors： Hwang WY,Koh LP,Ng HJ,Tan PH,Chuah CT,Fook SC,Chow H,Tan KW,Wong C,Tan CH,Goh YT

    更新日期：2004-07-01 00:00:00

  • Effect of in vivo therapy with a CD8 monoclonal antibody on delayed engraftment after autologous bone marrow transplantation.

    abstract：:Very long delay to engraftment (or non-engraftment) was observed in eight patients presenting common immunological features, i.e. excess of blood and bone marrow lymphocytes coexpressing CD8 and CD57 (HNK1) antigens. They were therefore treated by CD8 immunotherapy. Such treatment induced a complete clearance of CD8+,...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Favrot M,Philip T,Combaret V,Lemerle J,Marie JP,Bernard A

    更新日期：1990-01-01 00:00:00

  • Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation.

    abstract：:Autologous stem cell transplantation (PBSCT) is standard for young patients in MM and its TRM has decreased after the 2000s. Bortezomib and immunomodulatory agents (IMiDs) in MM have improved the outcome. However, they seem to boost pro-inflammatory stage increasing the incidence of engraftment syndrome (ES). Favorabl...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-018-0189-2

    authors： Gutiérrez-García G,Rovira M,Magnano L,Rosiñol L,Bataller A,Suárez-Lledó M,Cibeira MT,de Larrea CF,Garrote M,Jorge S,Moreno A,Rodríguez-Lobato LG,Carreras E,Díaz-Ricart M,Palomo M,Martínez C,Urbano-Ispizua A,Bladé J,Fe

    更新日期：2018-12-01 00:00:00

  • Functional aspects of cord blood lymphocytes response to polyclonal and allogeneic activation.

    abstract：:With the purpose of contributing to a better knowledge of the phenotypic characteristics and functional activity of umbilical cord blood (UCB) lymphocytes, we have carried out extensive immunophenotyping of these cells, evaluated their immune response to polyclonal and allogeneic activation and then compared these res...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Paiva A,Freitas A,Loureiro A,Couceiro A,Martinho A,Simões O,Santos P,Tomaz J,Pais ML,Brêda Coimbra H

    更新日期：1998-07-01 00:00:00

  • Autografting in Philadelphia (Ph)+ chronic myeloid leukaemia using cultured marrow: an update of a pilot study.

    abstract：:Incubation of CML marrow in long-term culture (LTC) conditions may result in selection of normal (Ph-) LTC-initiating cells (LTC-IC) as early as 10 days, and in production of Ph- clonogenic cells and mature end cells within 5 weeks. This was the rationale for using marrow cells from 10-day-old LTC to autograft nine ch...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700777

    authors： Coutinho LH,Chang J,Brereton ML,Morgenstern GR,Scarffe JH,Harrison CJ,Yin JA,Darbyshire PJ,Burdach S,Dexter TM,Testa NG

    更新日期：1997-05-01 00:00:00

  • M-CSF attenuates severity of chronic GVHD after unrelated BMT.

    abstract：:To study the effects of M-CSF administration on long-term outcomes of unrelated BMT, we retrospectively analyzed data from patients transplanted through the Japan Marrow Donor Program. We obtained data from 54 patients who received M-CSF just after BMT and 500 patients who did not receive M-CSF or G-CSF acted as contr...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2011.90

    authors： Kimura F,Sato K,Akiyama H,Sao H,Okamoto S,Kobayashi N,Hara M,Kawa K,Motoyoshi K,Japan Marrow Donor Program.

    更新日期：2012-03-01 00:00:00

  • Use of intrathecal chemoprophylaxis in children after SCT and the risk of central nervous system relapse.

    abstract：:Conflicting conclusions can be drawn from the available data concerning antileukemic efficacy and risks of intrathecal (i.t.) chemoprophylaxis to children after hematopoietic SCT (HSCT). To address this, we enrolled six transplantation centers with similar treatment and patient material. Of the 397 children included, ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/bmt.2010.121

    authors： Rubin J,Vettenranta K,Vettenranta J,Bierings M,Abrahamsson J,Békássy AN,Håkansson Y,Frost BM,Arvidson J,Spendilow C,Winiarski J,Gustafsson B

    更新日期：2011-03-01 00:00:00

  • Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.

    abstract：:BU and CY (BU/CY; 200 mg/kg) before HLA-matched sibling allo-SCT in children with sickle cell disease (SCD) is associated with ~85% EFS but is limited by the acute and late effects of BU/CY myeloablative conditioning. Alternatives include reduced toxicity but more immunosuppressive conditioning. We investigated in a p...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/bmt.2014.84

    authors： Bhatia M,Jin Z,Baker C,Geyer MB,Radhakrishnan K,Morris E,Satwani P,George D,Garvin J,Del Toro G,Zuckerman W,Lee MT,Licursi M,Hawks R,Smilow E,Baxter-Lowe LA,Schwartz J,Cairo MS

    更新日期：2014-07-01 00:00:00

  • Granulocyte-macrophage colony-stimulating factor-associated histiocytosis and capillary-leak syndrome following autologous bone marrow transplantation: two case reports and a review of the literature.

    abstract：:Bone marrow (BM) histiocystosis in association with the administration of granulocyte-macrophage colony-stimulating factor (GM-CSF) is a rare phenomenon with few published cases. We report two cases of BM histiocystosis in patients with Hodgkin's disease treated with GM-CSF after autologous bone marrow transplantation...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1701036

    authors： Al-Homaidhi A,Prince HM,Al-Zahrani H,Doucette D,Keating A

    更新日期：1998-01-01 00:00:00

  • First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party.

    abstract：:Extragonadal germ cell tumors are classified according to the staging system of the International Germ Cell Cancer Collaborative Group (IGCCCG). The 5-year overall and disease-free survival rates for poor prognosis patients are 41 and 48%, respectively after standard-dose chemotherapy. We report the experience of the ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704704

    authors： Rosti G,De Giorgi U,Wandt H,Lioure B,Leyvraz S,Kolbe K,Papiani G,Ballardini M,Kulekci A,Demirer T,Solid Tumours Working Party.

    更新日期：2004-12-01 00:00:00

  • High-dose melphalan +/- total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor.

    abstract：:The role of high-dose therapy and autologous stem cell transplantation (ASCT) in the treatment of patients with Ewing's sarcoma (EWS) remains uncertain. From November 1985 to September 1994, 13 patients aged 16-30 years (median 20.5) received high-dose melphalan (HDM) 140-200 mg/m2 +/- 500 cGy TBI followed by ASCT for...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Stewart DA,Gyonyor E,Paterson AH,Arthur K,Temple W,Schachar NS,Klassen J,Brown C,Russell JA

    更新日期：1996-08-01 00:00:00

  • Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG).

    abstract：:Forty-six children with juvenile myelomonocytic leukemia (JMML) diagnosed between 1978 and 1993 in 12 centers were retrospectively studied. There is no evidence that any conventional treatment influences the long-term evolution of JMML. Among 28 patients treated without bone marrow transplantation (BMT), 26 died (medi...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：

    authors： Lutz P,Zix-Kieffer I,Souillet G,Bertrand Y,Dhooge C,Rubie C,Mazingue F,Marguerite F,Machinaud-Lacroix F,Rialland X,Plouvier E,Behar C,Vilmer E,Philippe N,Otten J

    更新日期：1996-12-01 00:00:00